Funding for this research was provided by:
National Institutes of Health (HHSN268201300049C, HHSN268201300050C, HHSN268201300048C, HHSN268201300046C, HHSN268201300047C, HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, N01-HC-95169, UL1-TR-000040, UL1-TR-001079, UL1-TR-001420, UL1-TR-001881, DK063491, N02-HL-64278, UL1TR001881, DK063491, U01DK57292, U01DK57329, U01DK057300, U01DK057298, U01DK057249, U01DK57295, U01DK070657, U01DK057303, U01DK070657, U01DK57304, DK07024, HHSC268200782096C, DK081350, DK066358, DK053591, DK087914, DK105556, HL56266, DK070941, HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I, R01HL087641, R01HL086694, U01HG004402, HHSN268200625226C, UL1RR025005, HHSN268201300025C, HHSN268201300026C, HHSN268201300027C, HHSN268201300028C, HHSN268201300029C, HHSN268200900041C, AG0005, N01-HC-65226)
Wake Forest School of Medicine (M01 RR07122)
Received: 21 December 2018
Accepted: 11 April 2019
First Online: 15 May 2019
Ethics approval and consent to participate
: Analyses were approved by local institutional review boards, and all participants provided written informed consent.
: Not applicable.
: Wake Forest University Health Sciences and Barry Freedman have rights to an issued US patent related to <i>APOL1</i> gene testing. Dr. Freedman is a consultant for Ionis and AstraZeneca Pharmaceuticals.The other authors declare that they have no competing interests.The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.